AMYL THERAPEUTICS

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treat rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis and by neurodegenerative diseases... Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Also known as: Amyl Therapeutics, Inc.

Primary location: Seraing Belgium